Business of regenerative medicine: comparability and the regulatory revolution
Join our international panel for part two of their discussion.
In the second part of our expert panel on the business of regenerative medicine, learn more about how comparability and regulation can affect a regenerative medicine’s path to commercialization.
Plus, our panelists share their experiences of regulatory systems around the world.
Chaired by Michael May, CCRM, this panel discussion focuses on the key business challenges within regenerative medicine. Joining Michael were four leading voices in regenerative medicine and cell therapy, from research to manufacture: Robert Preti (Hitachi Chemical Advanced Therapeutics Solutions, LLC), Robert Jones (Fisher Bioservices), Carolyn Yeago (Georgia Institute of Technology) and Qasim Rafiq (UCL).